Skip to content

Released Nov 14, 2018, after the close

10-Q filed Nov 14, 2018, 45 days after period end · 0001564590-18-029555

Q3 2018 · 10-Q
Revenue$7.84M−55.2% vs Q3 2017+37.4% vs Q2 2018
Net Income-$10.24MN/M vs Q3 2017N/M vs Q2 2018
EPS Diluted-$21.26N/M vs Q3 2017N/M vs Q2 2018
Operating Income-$10,157,000N/M
Operating Cash Flowderived$47,573,000—
Free Cash Flowderived$47,214,000—
Margins · derived
Operating margin-129.6%−123.5 pt vs Q3 2017
Net margin-130.6%−122.5 pt vs Q3 2017

What the release said

The release

Same quarter

MetricQ3 2018Q3 2017
Revenue$7.84M$17.50M
Net Income-$10.24M-$1.42M
EPS Diluted-$21.26-$3.14

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Sutro Biopharma, Inc. · CIK 1382101 · Engraved from SEC EDGAR